189 related articles for article (PubMed ID: 38423748)
21. Modeling
Knochelmann HM; Rivera-Reyes AM; Wyatt MM; Smith AS; Chamness R; Dwyer CJ; Bobian M; Rangel Rivera GO; Horton JD; Lilly M; Romeo MJ; Timmers CD; Rubinstein MP; Neskey DM; Paulos CM
Oncoimmunology; 2021; 10(1):1959101. PubMed ID: 34408920
[TBL] [Abstract][Full Text] [Related]
22. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
[TBL] [Abstract][Full Text] [Related]
23. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner A; Corrie PG; Hamid O
Clin Cancer Res; 2023 May; 29(10):1835-1854. PubMed ID: 36485001
[TBL] [Abstract][Full Text] [Related]
24. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
25. Lifileucel: First Approval.
Keam SJ
Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract][Full Text] [Related]
27. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
Considine B; Hurwitz ME
Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
[TBL] [Abstract][Full Text] [Related]
28. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
29. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
[TBL] [Abstract][Full Text] [Related]
31. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.
Mullinax JE; Hall M; Beatty M; Weber AM; Sannasardo Z; Svrdlin T; Hensel J; Bui M; Richards A; Gonzalez RJ; Cox CA; Kelley L; Mulé JJ; Sarnaik AA; Pilon-Thomas S
J Immunother; 2021 Feb-Mar 01; 44(2):63-70. PubMed ID: 33443972
[TBL] [Abstract][Full Text] [Related]
32. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
Wang S; Sun J; Chen K; Ma P; Lei Q; Xing S; Cao Z; Sun S; Yu Z; Liu Y; Li N
BMC Med; 2021 Jun; 19(1):140. PubMed ID: 34112147
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
34. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
Diaz-Cano I; Paz-Ares L; Otano I
Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
[TBL] [Abstract][Full Text] [Related]
35. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
[TBL] [Abstract][Full Text] [Related]
36. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.
Gezgin G; Visser M; Ruano D; Santegoets SJ; de Miranda NFCC; van der Velden PA; Luyten GPM; van der Burg SH; Verdegaal EM; Jager MJ
Ophthalmol Sci; 2022 Jun; 2(2):100132. PubMed ID: 36249685
[TBL] [Abstract][Full Text] [Related]
38. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
39. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Aydin AM; Hall M; Bunch BL; Branthoover H; Sannasardo Z; Mackay A; Beatty M; Sarnaik AA; Mullinax JE; Spiess PE; Pilon-Thomas S
Int Immunopharmacol; 2021 May; 94():107481. PubMed ID: 33636562
[TBL] [Abstract][Full Text] [Related]
40. Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection.
Balzeau J; Ravindran A; Wang X; Maisuria J; Lucchesi A; Yao H; Matsueda S
Cancer Immunol Immunother; 2023 Oct; 72(10):3377-3385. PubMed ID: 37468658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
